Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...

Indian retail investors ramped up US stock purchases amid global market volatility, with a strong tilt toward semiconductors, ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been fil ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS ) securities between April 29, 2025 and June 23, 2025, both dates ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Minister Sharanprakash Patil ensures quality education at Haveri Institute of Medical Sciences, addressing issues and overseeing renovations.

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Hims & Hers Health is a top telehealth company with strong growth, innovation, and global expansion plans. See more on HIMS ...

Hims & Hers Health, Inc. (HIMS) reached $50.46 at the closing of the latest trading day, reflecting a -3.02% change compared to its last close.